Nxera Pharma Ltd. and Shionogi & Ltd just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Nxera Pharma Ltd. and Shionogi & Ltd, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Nxera Pharma and Shionogi's Partnership to Launch QUVIVIQ™ in Japan for Adults with Insomnia
Contract Type
partnership
TokyoBiotechnologyPharmaceuticalBiopharmaDescription
Nxera Pharma and Shionogi have announced the launch of QUVIVIQ™ (daridorexant) 25 and 50 mg in Japan for the treatment of adults with insomnia. Under the commercial partnership agreement, Shionogi will be solely responsible for the distribution and sales activities of QUVIVIQ™ in Japan, while Nxera Pharma's subsidiary will be the approval holder and be partially responsible for the provision of the drug product.